Characteristics analysis of cervical lymph node metastasis in papillary thyroid carcinoma coexisting with Hashimoto thyreoiditis: a literatures review_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DUAN Chengcheng , SHEN Keyu , XIAO Siqi , WU Xianji , YU Wenxi ,  ZHANG Guang

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University; Jilin Provincial Key Laboratory of Surgical Translational Medicine; Jilin Provincial Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun 130033, P. R. China;

Corresponding?author：

ZHANG Guang, Email: zhangguang@jlu.edu.cn

Keywords：

Hashimoto thyroiditis; thyroid papillary carcinoma; cervical lymph node metastasis; risk factor; ultrasonic characteristics

DOI：

10.7507/1007-9424.202308070

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the characteristics of cervical lymph node metastasis (LNM) in the papillary thyroid carcinoma (PTC) coexisting with Hashimoto thyroiditis (HT). Method The literatures related to cervical LNM of PTC coexisting with HT in recent years were collected and summarized. Results Compared with the PTC patients without HT, the more enlarged lymph nodes could be detected, and the cervival central LNM rate was lower, but there was still controversy about cervival lateral LNM in the patients with PTC coexisting with HT. The male, young, large tumor diameter, extraglandular invasion, multifocal cancer, BRAF gene mutation, and higher thyroid peroxidase antibody and thyroglobulin antibody levels, as well as the ultrasound features such as thyroid nodule aspect ratio >1, extremely low echo, calcification, and lymph node calcification, liquefaction, and disappearance of hilar lymph nodes could be used to evaluate the risk factors of cervical LNM for the patients with PTC coexisting with HT. Conclusions From the results of this review, it is suggests that the rate of central LNM is lower in patients with PTC coexisting with HT, but the status of LNM in the cervical lateral region remains to be explored. The relevant risk factors in combination with ultrasonic characteristics could help evaluate cervical lymph node status, could provide basis for early detection of metastatic lymph nodes and the formulation of individualized surgical plans, and improve the prognosis of patients.

Citation： DUAN Chengcheng, SHEN Keyu, XIAO Siqi, WU Xianji, YU Wenxi, ZHANG Guang. Characteristics analysis of cervical lymph node metastasis in papillary thyroid carcinoma coexisting with Hashimoto thyreoiditis: a literatures review. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(12): 1507-1513. doi: 10.7507/1007-9424.202308070 Copy

1.	Bliddal S, Nielsen CH, Feldt-Rasmussen U. Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res, 2017, 6: 1776.
2.	Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg, 1955, 70(2): 291-297.
3.	Chen J, Li XL, Zhao CK, et al. Conventional ultrasound, immunohistochemical factors and BRAF^V600E mutation in predicting central cervical lymph node metastasis of papillary thyroid carcinoma. Ultrasound Med Biol, 2018, 44(11): 2296-2306.
4.	Pagano L, Mele C, Sama MT, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity. Front Biosci (Landmark Ed), 2018, 23(12): 2267-2282.
5.	Uhliarova B, Hajtman A. Hashimoto’s thyroiditis—an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol, 2018, 84(6): 729-735.
6.	Konturek A, Barczyński M, Wierzchowski W, et al. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg, 2013, 398(3): 389-394.
7.	Xu JY, Ding K, Mu L, et al. Hashimoto’s thyroiditis: a “Double-Edged Sword” in thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 801925.
8.	吳佳奇, 王虹, 杜琳瑤, 等. 橋本甲狀腺炎合并甲狀腺乳頭狀癌超聲特征與頸部淋巴結轉移的相關性研究. 哈爾濱醫科大學學報, 2018, 52(4): 387-390.
9.	Abbasgholizadeh P, Naseri A, Nasiri E, et al. Is Hashimoto thyroiditis associated with increasing risk of thyroid malignancies? A systematic review and meta-analysis. Thyroid Res, 2021, 14(1): 26.
10.	譚碧星. 橋本氏甲狀腺炎背景下甲狀腺乳頭狀癌的超聲特征、BRAF^V600E突變及侵襲性情況的研究. 張家口: 河北北方學院, 2022.
11.	Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
12.	Wen X, Wang B, Jin Q, et al. Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with Hashimoto’s thyroiditis. Ann Surg Oncol, 2019, 26(6): 1751-1758.
13.	Liang J, Zeng W, Fang F, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1 392 patients. Acta Otorhinolaryngol Ital, 2017, 37(5): 393-400.
14.	Lai V, Yen TW, Rose BT, et al. The effect of thyroiditis on the yield of central compartment lymph nodes in patients with papillary thyroid cancer. Ann Surg Oncol, 2015, 22(13): 4181-4186.
15.	Sulaieva O, Selezniov O, Shapochka D, et al. Hashimoto’s thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. Heliyon, 2020, 6(1): e03077.
16.	Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg, 2001, 25(5): 632-637.
17.	Zhu F, Shen YB, Li FQ, et al. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study. Medicine (Baltimore), 2016, 95(6): e2674.
18.	Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg, 2016, 28 Suppl 1: S70-S74. doi: 10.1016/j.ijsu.2015.12.059.
19.	Song E, Jeon MJ, Park S, et al. Influence of coexistent Hashimoto’s thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2018, 88(1): 123-128.
20.	Wang L, Chen J, Yuan X, et al. Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto’s thyroiditis. BMC Endocr Disord, 2022, 22(1): 12.
21.	Liu Y, Lv H, Zhang S, et al. The impact of coexistent Hashimoto’s thyroiditis on central compartment lymph node metastasis in papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2021, 12: 772071.
22.	Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma. Otolaryngol Head Neck Surg, 2012, 147(3): 444-449.
23.	鄭荊洲, 童傳明, 吳高松. 微小甲狀腺癌合并橋本氏甲狀腺炎的臨床病理及頸淋巴結轉移特征. 中國普通外科雜志, 2014, 23(11): 1557-1560.
24.	Donangelo I, Walts AE, Bresee C, et al. Lymphocytic thyroiditis is associated with increased number of benign cervical nodes and fewer central neck compartment metastatic lymph nodes in patients with differentiated thyroid cancer. Endocr Pract, 2016, 22(10): 1192-1198.
25.	車勇軍, 連蕾, 侯鈺, 等. 橋本氏甲狀腺炎合并甲狀腺乳頭狀癌患者的臨床病理特征及其與BRAF基因突變的相關性研究. 中國耳鼻咽喉頭頸外科, 2023, 30(2): 69-73.
26.	王歡, 柴芳, 林本瑞, 等. 合并橋本甲狀腺炎的甲狀腺乳頭狀癌中央區淋巴結轉移的危險因素. 中國老年學雜志, 2021, 41(7): 1396-1399.
27.	劉文, 程若川. 甲狀腺乳頭狀癌中央區淋巴結轉移的預測因素. 中國普外基礎與臨床雜志, 2018, 25(1): 99-103.
28.	邱麗湞, 邱友燕, 陳曉珠, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎臨床病理特征及頸部淋巴結轉移影響因素分析. 廣州醫科大學學報, 2022, 50(3): 70-75.
29.	Sun Y, Lv H, Zhang S, et al. Gender-specific risk of central compartment lymph node metastasis in papillary thyroid carcinoma. Int J Endocrinol, 2018, 2018: 6710326.
30.	Eldien MMS, Abdou AG, Rageh T, et al. Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma. Ecancermedicalscience, 2017, 11: 748.
31.	張廣, 張純海, 付言濤, 等. 甲狀腺炎合并甲狀腺癌頸淋巴結轉移情況及相關因素探討. 中國普外基礎與臨床雜志, 2011, 18(6): 625-628.
32.	Zhou L, Chen G, Sheng L, et al. Influence factors for lymph node metastasis in papillary thyroid carcinoma: Hashimoto’s thyroiditis has a weak effect on central or lateral lymph node metastasis. Cancer Manag Res, 2021, 13: 3953-3961.
33.	趙凱軍, 葛冠男, 鄭美娜, 等. 橋本甲狀腺炎合并其他甲狀腺疾病的年齡分布研究. 中國地方病防治雜志, 2016, 31(11): 1216-1218.
34.	丁金旺, 潘鋼, 項洋鋒, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎患側中央區淋巴結轉移的臨床危險因素分析. 浙江醫學, 2021, 43(15): 1643-1646,1651.
35.	Zeng B, Min Y, Feng Y, et al. Hashimoto’s thyroiditis is associated with central lymph node metastasis in classical papillary thyroid cancer: analysis from a high-volume single-center experience. Front Endocrinol (Lausanne), 2022, 13: 868606.
36.	Amin MB, Greene FL, Edge SB. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
37.	Chen S, Niu C, Peng Q, et al. Sonographic characteristics of papillary thyroid carcinoma with coexistent Hashimoto’s thyroiditis in the preoperative prediction of central lymph node metastasis. Front Endocrinol (Lausanne), 2021, 12: 556851. doi: 10.3389/fendo.2021.556851.
38.	Konturek A, Barczyński M, Nowak W, et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis. Langenbecks Arch Surg, 2014, 399(2): 229-236.
39.	Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto’s thyroiditis. Am J Cancer Res, 2019, 9(8): 1786-1795.
40.	Dong S, Xia Q, Wu YJ. High TPOAb levels (>1 300 IU/mL) indicate multifocal PTC in Hashimoto’s thyroiditis patients and support total thyroidectomy. Otolaryngol Head Neck Surg, 2015, 153(1): 20-26.
41.	Min Y, Huang Y, Wei M, et al. Preoperatively predicting the central lymph node metastasis for papillary thyroid cancer patients with Hashimoto’s thyroiditis. Front Endocrinol (Lausanne), 2021, 12: 713475.
42.	Shen CT, Zhang XY, Qiu ZL, et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine, 2017, 58(1): 176-183.
43.	Paparodis R, Imam S, Todorova-Koteva K, et al. Hashimoto’s thyroiditis pathology and risk for thyroid cancer. Thyroid, 2014, 24(7): 1107-1114.
44.	Vasileiadis I, Boutzios G, Charitoudis G, et al. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol, 2014, 21(8): 2725-2732.
45.	Lubin D, Baraban E, Lisby A, et al. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr Pathol, 2018, 29(4): 317-323.
46.	羅雪, 趙代偉, 陳松, 等. 程序性細胞死亡配體1在甲狀腺乳頭狀癌合并橋本甲狀腺炎中的表達及其臨床意義. 中國普外基礎與臨床雜志, 2021, 28(9): 1155-1158.
47.	Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAF^V600E in papillary thyroid carcinoma. Endocr Relat Cancer, 2016, 23(1): 27-34.
48.	Zhao W, He L, Zhu J, et al. A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto’s thyroiditis to predict central lymph node metastasis. Clin Endocrinol (Oxf), 2021, 94(2): 310-321.
49.	何慶蘭, 李世櫻, 劉林玲. 超聲檢查橋本甲狀腺炎合并甲狀腺乳頭狀癌頸部淋巴結轉移的價值. 醫學影像學雜志, 2018, 28(12): 2000-2003.
50.	Kim SW, Jin HL, Kang SM, et al. Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair. Int J Cardiol, 2016, 203: 498-507.
51.	林婉玲, 雷志鍇, 丁金旺, 等. 預測橋本甲狀腺炎背景下甲狀腺乳頭狀癌超聲特征與中央區淋巴結轉移的價值. 浙江醫學, 2021, 43(7): 748-752.
52.	楊濤, 朱世琴, 劉慧, 等. VTIQ聯合US-FNAB對橋本甲狀腺炎合并甲狀腺乳頭狀癌頸部中央區淋巴結性質判定的價值. 現代腫瘤醫學, 2022, 30(21): 3887-3892.
53.	Tan HL, Nyarko A, Duan SL, et al. Comprehensive analysis of the effect of Hashimoto’s thyroiditis on the diagnostic efficacy of preoperative ultrasonography on cervical lymph node lesions in papillary thyroid cancer. Front Endocrinol (Lausanne), 2023, 13: 987906.
54.	庹菁菁, 于詩香. 超聲對橋本甲狀腺炎合并甲狀腺乳頭狀癌患者頸部淋巴結轉移的診斷價值. 影像研究與醫學應用, 2019, 3(14): 145-147.
55.	Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. Eur J Radiol, 2019, 112: 14-21.
56.	Feng N, Wei P, Kong X, et al. The value of ultrasound grayscale ratio in the diagnosis of papillary thyroid microcarcinomas and benign micronodules in patients with Hashimoto’s thyroiditis: a two-center controlled study. Front Endocrinol (Lausanne), 2022, 13: 949847.
57.	趙海娜, 馬步云, 駱洪浩. 超聲彈性成像技術對伴或不伴橋本甲狀腺炎的甲狀腺微小結節良惡性的鑒別診斷價值. 中國普外基礎與臨床雜志, 2017, 24(11): 1342-1346.
58.	Fang F, Gong Y, Liao L, et al. Value of contrast-enhanced ultrasound for evaluation of cervical lymph node metastasis in papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 812475.

1. Bliddal S, Nielsen CH, Feldt-Rasmussen U. Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res, 2017, 6: 1776.
2. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg, 1955, 70(2): 291-297.
3. Chen J, Li XL, Zhao CK, et al. Conventional ultrasound, immunohistochemical factors and BRAF^V600E mutation in predicting central cervical lymph node metastasis of papillary thyroid carcinoma. Ultrasound Med Biol, 2018, 44(11): 2296-2306.
4. Pagano L, Mele C, Sama MT, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity. Front Biosci (Landmark Ed), 2018, 23(12): 2267-2282.
5. Uhliarova B, Hajtman A. Hashimoto’s thyroiditis—an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol, 2018, 84(6): 729-735.
6. Konturek A, Barczyński M, Wierzchowski W, et al. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg, 2013, 398(3): 389-394.
7. Xu JY, Ding K, Mu L, et al. Hashimoto’s thyroiditis: a “Double-Edged Sword” in thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 801925.
8. 吳佳奇, 王虹, 杜琳瑤, 等. 橋本甲狀腺炎合并甲狀腺乳頭狀癌超聲特征與頸部淋巴結轉移的相關性研究. 哈爾濱醫科大學學報, 2018, 52(4): 387-390.
9. Abbasgholizadeh P, Naseri A, Nasiri E, et al. Is Hashimoto thyroiditis associated with increasing risk of thyroid malignancies? A systematic review and meta-analysis. Thyroid Res, 2021, 14(1): 26.
10. 譚碧星. 橋本氏甲狀腺炎背景下甲狀腺乳頭狀癌的超聲特征、BRAF^V600E突變及侵襲性情況的研究. 張家口: 河北北方學院, 2022.
11. Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
12. Wen X, Wang B, Jin Q, et al. Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with Hashimoto’s thyroiditis. Ann Surg Oncol, 2019, 26(6): 1751-1758.
13. Liang J, Zeng W, Fang F, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1 392 patients. Acta Otorhinolaryngol Ital, 2017, 37(5): 393-400.
14. Lai V, Yen TW, Rose BT, et al. The effect of thyroiditis on the yield of central compartment lymph nodes in patients with papillary thyroid cancer. Ann Surg Oncol, 2015, 22(13): 4181-4186.
15. Sulaieva O, Selezniov O, Shapochka D, et al. Hashimoto’s thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. Heliyon, 2020, 6(1): e03077.
16. Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg, 2001, 25(5): 632-637.
17. Zhu F, Shen YB, Li FQ, et al. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study. Medicine (Baltimore), 2016, 95(6): e2674.
18. Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg, 2016, 28 Suppl 1: S70-S74. doi: 10.1016/j.ijsu.2015.12.059.
19. Song E, Jeon MJ, Park S, et al. Influence of coexistent Hashimoto’s thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2018, 88(1): 123-128.
20. Wang L, Chen J, Yuan X, et al. Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto’s thyroiditis. BMC Endocr Disord, 2022, 22(1): 12.
21. Liu Y, Lv H, Zhang S, et al. The impact of coexistent Hashimoto’s thyroiditis on central compartment lymph node metastasis in papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2021, 12: 772071.
22. Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma. Otolaryngol Head Neck Surg, 2012, 147(3): 444-449.
23. 鄭荊洲, 童傳明, 吳高松. 微小甲狀腺癌合并橋本氏甲狀腺炎的臨床病理及頸淋巴結轉移特征. 中國普通外科雜志, 2014, 23(11): 1557-1560.
24. Donangelo I, Walts AE, Bresee C, et al. Lymphocytic thyroiditis is associated with increased number of benign cervical nodes and fewer central neck compartment metastatic lymph nodes in patients with differentiated thyroid cancer. Endocr Pract, 2016, 22(10): 1192-1198.
25. 車勇軍, 連蕾, 侯鈺, 等. 橋本氏甲狀腺炎合并甲狀腺乳頭狀癌患者的臨床病理特征及其與BRAF基因突變的相關性研究. 中國耳鼻咽喉頭頸外科, 2023, 30(2): 69-73.
26. 王歡, 柴芳, 林本瑞, 等. 合并橋本甲狀腺炎的甲狀腺乳頭狀癌中央區淋巴結轉移的危險因素. 中國老年學雜志, 2021, 41(7): 1396-1399.
27. 劉文, 程若川. 甲狀腺乳頭狀癌中央區淋巴結轉移的預測因素. 中國普外基礎與臨床雜志, 2018, 25(1): 99-103.
28. 邱麗湞, 邱友燕, 陳曉珠, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎臨床病理特征及頸部淋巴結轉移影響因素分析. 廣州醫科大學學報, 2022, 50(3): 70-75.
29. Sun Y, Lv H, Zhang S, et al. Gender-specific risk of central compartment lymph node metastasis in papillary thyroid carcinoma. Int J Endocrinol, 2018, 2018: 6710326.
30. Eldien MMS, Abdou AG, Rageh T, et al. Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma. Ecancermedicalscience, 2017, 11: 748.
31. 張廣, 張純海, 付言濤, 等. 甲狀腺炎合并甲狀腺癌頸淋巴結轉移情況及相關因素探討. 中國普外基礎與臨床雜志, 2011, 18(6): 625-628.
32. Zhou L, Chen G, Sheng L, et al. Influence factors for lymph node metastasis in papillary thyroid carcinoma: Hashimoto’s thyroiditis has a weak effect on central or lateral lymph node metastasis. Cancer Manag Res, 2021, 13: 3953-3961.
33. 趙凱軍, 葛冠男, 鄭美娜, 等. 橋本甲狀腺炎合并其他甲狀腺疾病的年齡分布研究. 中國地方病防治雜志, 2016, 31(11): 1216-1218.
34. 丁金旺, 潘鋼, 項洋鋒, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎患側中央區淋巴結轉移的臨床危險因素分析. 浙江醫學, 2021, 43(15): 1643-1646,1651.
35. Zeng B, Min Y, Feng Y, et al. Hashimoto’s thyroiditis is associated with central lymph node metastasis in classical papillary thyroid cancer: analysis from a high-volume single-center experience. Front Endocrinol (Lausanne), 2022, 13: 868606.
36. Amin MB, Greene FL, Edge SB. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
37. Chen S, Niu C, Peng Q, et al. Sonographic characteristics of papillary thyroid carcinoma with coexistent Hashimoto’s thyroiditis in the preoperative prediction of central lymph node metastasis. Front Endocrinol (Lausanne), 2021, 12: 556851. doi: 10.3389/fendo.2021.556851.
38. Konturek A, Barczyński M, Nowak W, et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis. Langenbecks Arch Surg, 2014, 399(2): 229-236.
39. Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto’s thyroiditis. Am J Cancer Res, 2019, 9(8): 1786-1795.
40. Dong S, Xia Q, Wu YJ. High TPOAb levels (>1 300 IU/mL) indicate multifocal PTC in Hashimoto’s thyroiditis patients and support total thyroidectomy. Otolaryngol Head Neck Surg, 2015, 153(1): 20-26.
41. Min Y, Huang Y, Wei M, et al. Preoperatively predicting the central lymph node metastasis for papillary thyroid cancer patients with Hashimoto’s thyroiditis. Front Endocrinol (Lausanne), 2021, 12: 713475.
42. Shen CT, Zhang XY, Qiu ZL, et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine, 2017, 58(1): 176-183.
43. Paparodis R, Imam S, Todorova-Koteva K, et al. Hashimoto’s thyroiditis pathology and risk for thyroid cancer. Thyroid, 2014, 24(7): 1107-1114.
44. Vasileiadis I, Boutzios G, Charitoudis G, et al. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol, 2014, 21(8): 2725-2732.
45. Lubin D, Baraban E, Lisby A, et al. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr Pathol, 2018, 29(4): 317-323.
46. 羅雪, 趙代偉, 陳松, 等. 程序性細胞死亡配體1在甲狀腺乳頭狀癌合并橋本甲狀腺炎中的表達及其臨床意義. 中國普外基礎與臨床雜志, 2021, 28(9): 1155-1158.
47. Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAF^V600E in papillary thyroid carcinoma. Endocr Relat Cancer, 2016, 23(1): 27-34.
48. Zhao W, He L, Zhu J, et al. A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto’s thyroiditis to predict central lymph node metastasis. Clin Endocrinol (Oxf), 2021, 94(2): 310-321.
49. 何慶蘭, 李世櫻, 劉林玲. 超聲檢查橋本甲狀腺炎合并甲狀腺乳頭狀癌頸部淋巴結轉移的價值. 醫學影像學雜志, 2018, 28(12): 2000-2003.
50. Kim SW, Jin HL, Kang SM, et al. Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair. Int J Cardiol, 2016, 203: 498-507.
51. 林婉玲, 雷志鍇, 丁金旺, 等. 預測橋本甲狀腺炎背景下甲狀腺乳頭狀癌超聲特征與中央區淋巴結轉移的價值. 浙江醫學, 2021, 43(7): 748-752.
52. 楊濤, 朱世琴, 劉慧, 等. VTIQ聯合US-FNAB對橋本甲狀腺炎合并甲狀腺乳頭狀癌頸部中央區淋巴結性質判定的價值. 現代腫瘤醫學, 2022, 30(21): 3887-3892.
53. Tan HL, Nyarko A, Duan SL, et al. Comprehensive analysis of the effect of Hashimoto’s thyroiditis on the diagnostic efficacy of preoperative ultrasonography on cervical lymph node lesions in papillary thyroid cancer. Front Endocrinol (Lausanne), 2023, 13: 987906.
54. 庹菁菁, 于詩香. 超聲對橋本甲狀腺炎合并甲狀腺乳頭狀癌患者頸部淋巴結轉移的診斷價值. 影像研究與醫學應用, 2019, 3(14): 145-147.
55. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. Eur J Radiol, 2019, 112: 14-21.
56. Feng N, Wei P, Kong X, et al. The value of ultrasound grayscale ratio in the diagnosis of papillary thyroid microcarcinomas and benign micronodules in patients with Hashimoto’s thyroiditis: a two-center controlled study. Front Endocrinol (Lausanne), 2022, 13: 949847.
57. 趙海娜, 馬步云, 駱洪浩. 超聲彈性成像技術對伴或不伴橋本甲狀腺炎的甲狀腺微小結節良惡性的鑒別診斷價值. 中國普外基礎與臨床雜志, 2017, 24(11): 1342-1346.
58. Fang F, Gong Y, Liao L, et al. Value of contrast-enhanced ultrasound for evaluation of cervical lymph node metastasis in papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 812475.

Previous Article
Progress of relationship between ferroptosis and acute liver injury
Next Article
Progress in diagnosis and treatment of granulomatous lobular mastitis

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Characteristics analysis of cervical lymph node metastasis in papillary thyroid carcinoma coexisting with Hashimoto thyreoiditis: a literatures review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content